What Now for the Endovascular Community After the Paclitaxel Mortality Meta-Analysis: Can Sirolimus Replace Paclitaxel in the Peripheral Vasculature?

Tjun Y Tang; Edward C Choke; Stewart R Walsh; Alok Tiwari; Tze T Chong

doi:10.1177/1526602819881156

What Now for the Endovascular Community After the Paclitaxel Mortality Meta-Analysis: Can Sirolimus Replace Paclitaxel in the Peripheral Vasculature?

J Endovasc Ther. 2020 Feb;27(1):153-156. doi: 10.1177/1526602819881156. Epub 2019 Oct 14.

Authors

Tjun Y Tang¹, Edward C Choke², Stewart R Walsh³, Alok Tiwari⁴, Tze T Chong¹

Affiliations

¹ Duke-NUS Medical School, Department of Vascular Surgery, Singapore General Hospital, Singapore, Singapore.
² Department of General Surgery, Sengkang General Hospital, Singapore.
³ Department of Vascular Surgery, Galway University Hospital, Ireland.
⁴ Department of Vascular Surgery, Queen Elizabeth Hospital, Birmingham, UK.

PMID: 31608741
DOI: 10.1177/1526602819881156

No abstract available

Keywords: drug-coated balloon; drug-eluting stent; drug-eluting technology; femoropopliteal segment; mortality; paclitaxel; sirolimus; superficial femoral artery.

Publication types

Editorial
Comment

MeSH terms

Femoral Artery
Paclitaxel*
Popliteal Artery
Randomized Controlled Trials as Topic
Sirolimus*
Stents
Treatment Outcome

Substances

Paclitaxel
Sirolimus